Upfront Briefing
Thursday was the hangover, and what turned up in place of Wednesday's fireworks was capital expenditure: Roche committing $750M to an Oregon plant that will not fill a syringe until 2031. Long-dated conviction, or a very expensive way of saying the obesity molecules had better work.
The more telling pair came from the discovery layer. Bristol Myers Squibb became the fourth Big Pharma to rent Chai Discovery's AI models — no exclusivity, no disclosed terms — on roughly the same day Amgen walked away from half a billion in TScan milestones. Pharma has worked out it would rather lease the capability than marry it.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,641.2 |
(0.9%) |
11.6% |
| Nasdaq 100 |
29,213.2 |
(0.7%) |
15.9% |
| Russell 2000 |
2,992.4 |
(1.3%) |
20.6% |
| Healthcare (XLV) |
172.4 |
(1.9%) |
10.9% |
| Biotech (XBI) |
163.4 |
(3.6%) |
34.4% |
| Nasdaq Biotech (NBI) |
7,188.5 |
(2.9%) |
26.0% |
| Clinical Trials (BBC) |
53.9 |
(3.9%) |
43.2% |
|
- Biotech unwound Wednesday's squeeze rather than sold off on news: XBI gave back 3.64% and NBI 2.92% against gains of 5.90% and 6.39% the prior session, as the Moderna/Merck intismeran trade retraced and Leerink's Daina Graybosch called the reaction overly optimistic. XLV's 1.87% decline was the milder version of the same round trip.
- The broad tape de-risked without a fear bid: the S&P fell 0.87% and the Nasdaq 100 0.72%, but VIX dropped 1.94% to 15.71 and gold added 1.57% to $4,643. The 10-year held at 4.692% while TLT slipped 0.82%, so the Treasury's 19 August buyback expansion faded at the long end rather than the belly, with Trump's Iran announcement keeping crude bid.
- Market data: U.S. cash close Thursday, 20 August 2026.
The Big 3
|
1
|
Roche commits $750M to a device plant that opens in 2031
|
- Genentech will spend roughly $750M to double its 75-acre Hillsboro, Oregon campus and add end-to-end device fill-finish for prefilled syringes and autoinjectors, creating 250 manufacturing jobs and 200 construction roles, with commercial operations slated for 2031.
- Why it matters: Fill-finish is the bottleneck nobody prices until it binds. Roche is spending $750M to double Hillsboro and add end-to-end device filling — prefilled syringes and autoinjectors — with commercial operations not until 2031, which tells you how long the queue for aseptic device capacity now runs. Read it against Holly Springs, the North Carolina site Roche has scaled specifically for metabolic and obesity products: Basel is building the delivery layer before it has the molecules. For device and component suppliers such as Catalent, Vetter and West Pharmaceutical, that is demand signal rather than competition. The offset is $750M of capex that earns nothing before 2031.
- Source: Fierce Pharma
- More: BioSpace; Roche
|
|
2
|
BMS becomes the fourth Big Pharma to rent Chai's AI models
|
- Bristol Myers Squibb will use Chai Discovery's molecular folding and design models to run therapeutic antibody discovery, joining Lilly, Novartis and Pfizer as Chai partners; targets, disease areas and financial terms were not disclosed.
- Why it matters: BMS is the fourth Big Pharma to buy Chai's models rather than lock them up, and that non-exclusivity is the tell: the AI-discovery layer is consolidating into a few vendors who sell to everyone. Chai's $400M Series C last month valued it at $3.8B on more than $600M raised, with no clinical asset — the platform is the revenue. No disclosed terms means no biobucks headline to discount, which cuts both ways on how seriously to take it. Set it against Amgen exiting TScan the same week and the shape is clear: pharma is renting discovery capability instead of buying target-discovery partnerships with milestone tails.
- Source: Fierce Biotech
- More: Chai Discovery
|
| 3 | Amgen walks away from $500M+ TScan Crohn's discovery pact |
- TScan disclosed in an 18 August 8-K that Amgen is terminating their May 2023 Crohn's disease target-discovery collaboration effective 10 November; Amgen paid $30M upfront and TScan had been eligible for milestones topping $500M.
- Why it matters: Second inflammation exit Amgen has made this year, after handing rocatinlimab back to Kyowa Kirin in January on a $400M pact. The pattern matters more than the dollars: Amgen's stated reason, a strategic review of research priorities, is the language of a company narrowing early discovery spend rather than one that lost faith in a single target. TScan takes no P&L hit — it kept no obligation, reported $100.2M in cash at end-June, runway into Q2 2027, and its lead TCR-T is now in Phase 3 in AML/MDS. The read-through runs to every platform biotech carrying Big Pharma discovery milestones on a valuation slide.
- Source: Fierce Biotech
- More: SEC 8-K
|
Everything Else that broke
- FDA granted PMA to Implantica's RefluxStop, opening the U.S. market. — PR
- Xspray took its third Dasynoc CRL in three years over GMP observations at Italian contract manufacturer NerPharMa; the FDA raised no questions on clinical data, bioequivalence or stability. — Fierce Pharma
- The FDA rejected Osteal's Nexchange Kit for periprosthetic joint infection over trial-design deficiencies and unresolved fungal PJI risk, stalling a launch Zimmer Biomet and J&J Innovation had funded. — Endpoints
- The FDA granted De Novo authorization to Vitestro's Aletta, the first standalone robotic blood-draw device, with one phlebotomist able to supervise three units and a 94.5% first-stick rate in the pivotal. — MedTech Dive
- Leerink's Daina Graybosch called the market's $45B re-rating of Moderna overly optimistic, arguing the implied adjuvant sales exceed what Keytruda earns in that setting today. — BioPharma Dive
- FDA cleared C2N's PrecivityAD2 Alzheimer's blood test for patients as young as 40. — PR
- Akeso's AK157D1 B7-H3 ADC cleared Phase 1 in solid tumors. — PR
- Boehringer suspended a phase 1 trial of an investigational small molecule to examine a safety event, declining to characterise the incident. — Fierce Biotech
- A study found gray-market copies of Lilly's triple-G retatrutide produced relatively poor weight loss. — Endpoints
- Spain, Denmark and the U.K. are building faster lanes for first-in-human trials. — BioCentury
- The FDA is widening its TEMPO-style path for digital health devices. — Endpoints
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Bristol Myers Squibb signed an AI antibody discovery collaboration with Chai Discovery covering undisclosed targets; terms undisclosed. — Fierce Biotech
-
Amgen terminated its May 2023 Crohn's target-discovery collaboration with TScan effective 10 November, ending eligibility for milestones above $500M against $30M paid upfront. — Fierce Biotech
-
Lilly licensed Amplitude Therapeutics' trans-amplifying RNA platform for undisclosed infectious disease vaccine targets, with an option on two more; terms undisclosed. — Fierce Biotech
-
WuXi Bio will sell its 51.1% stake in Bestchrom to an unnamed third party. — Endpoints
VC / Private Financings
- No notable private financings in the last 24 hours.
IPOs / Follow-Ons
- Scribe Therapeutics closed Wednesday at $31.05, 43% above its $21.50 first-day price, a month after its $129M Nasdaq IPO priced at $15; the XBI gained 12% over the same stretch. — BioSpace
Academic Corner - Liver resection after atezolizumab and bevacizumab prolonged time to treatment failure in advanced hepatocellular carcinoma in the phase 3 TALENTOP trial. — Lancet
- An off-the-shelf mutant KRAS vaccine triggered durable T cell responses in high-risk people in a phase 1 study. — Nature Medicine
- A nationwide analysis found county surveillance missed school-level measles epidemic thresholds before the 2025–2026 outbreaks. — Nature Medicine
|
